VCCircle’s Post

PharmEasy Once Valued $5.5 B, Now valued at $770M after current capital raise. CCI coming to sign off few investment. There were so much big intervention happened in e-pharmacy, 1. Flipkart acquired major stake in SastaSundar 2. Zeno Health earlier Generico acquired TABLT Pharmacy 3. Tata acquired Tata 1mg 4. Reliance Retail acquired Netmeds.com. 5. MEDLIFE merge with PharmEasy. 6. MedPlus Health Services Limited and Apollo Hospitals already in E-pharmacy race and more importantly franchise race being followed by all major players. several more in e-pharmacy model. Interestingly, PharmEasy has got so much local and big player competition and its own investor devalued several times from its peak 5.5B in last 2 years. I am excited to know the impact on Thyrocare Technologies Ltd. on secondary market after parent got shock in current. PharmEasy got default on debt of Goldman Sachs, lead to 50 percent devaluation by own investor. Now, new issue raise lead to 90 percent deduction. Please follow me, if you like content Raja Bose

**Emcure Pharmaceuticals Limited IPO** 📅 **Date**: 3-5 July, 2024 💵 **Price Band**: ₹796-₹810 📦 **Market Lot**: 14 Shares 💸 **Application Amount**: ₹14,112 📊 **Size**: ₹1,952 Cr Approx 👥 **Retail Portion**: 35% 📝 **Retail Form**: 4,81,654 👤 **HNI Small Form**: 4,587 👥 **HNI Big Form**: 9,174 🔖 **Face Value**: ₹10 **Bansal Wire Industries Limited IPO** 📅 **Date**: 3-5 July, 2024 💵 **Price Band**: ₹243-₹256 📦 **Market Lot**: 58 Shares 💸 **Application Amount**: ₹14,848 📊 **Size**: ₹745 Cr Approx 👥 **Retail Portion**: 35% 📝 **Retail Form**: 1,75,613 👤 **HNI Small Form**: 1,792 👥 **HNI Big Form**: 3,584 🔖 **Face Value**: ₹75 #IPO #StockMarket #Investing #Finance #EmcurePharma #BansalWire #MarketUpdate #StockNews #InvestmentOpportunity #NewIPO #FinancialGrowth #MarketTrends #FinancialServices #Growth #India #NBFC #IPOAnnouncement #FinanceNews #Banking #Insurance #FinancialEducation #TradingTips #MarketInsights #InvestmentStrategy #StocksToWatch 🔔 Don't miss out on this opportunity! 🔔 Stay tuned for more updates! . Follow 👉 @stock.insighthub . Turn on notifications for more updates 📢📢 Please share with your trader friends 🙂 . **Disclaimer:** The vision of @stock.insighthub is to promote financial literacy in India. The content we provide is intended purely for educational and entertainment purposes. Please note that we are not registered with the Securities and Exchange Board of India (SEBI) as financial advisors. Consequently, we do not offer any form of investment or financial advisory services. It is essential to recognize that you, as an investor, bear sole responsibility for your financial decisions and the management of your funds. For personalized financial guidance, we strongly advise consulting with a SEBI-registered financial advisor.

Robust System n process in place with immense passion can create miracles

Research, persistence, and due diligence are the pillars of success in buying pharmacies from corporates. Learn from seasoned entrepreneurs Vaibhav Chhatwal and Ram Parimi as they share their expertise on seizing opportunities in the pharmacy sector. Read the full article with RxBridge here. #CorporateAcquisitions #PharmacyGrowth #PartneredContent https://ow.ly/5nOp50QZntM

Innova Captab IPO Pops on Day 1! Is it Time to Get Your Rx? #InnovaCaptabIPO #PharmaPop #HealthWealth #MarketBuzz #InvestSmart #RetailRush #QIBCautious #NonInstitutionalNibble #IPOThrills Innova Captab's IPO sizzled like a freshly popped vitamin D gummy on its first day, getting subscribed 1.40 times! That means investors gobbled up more shares than the company initially offered, a sign of confidence in the pharma giant's future. Instagram: #IPOgram #StockMarketSelfie #FinancialFitness #HealthcareHero Twitter: #PharmaNews #MarketTrends #InvestingTips #BullishBelievers YouTube: #IPOAnalysis #InvestmentInsights #FinanceTalk #InnovaCaptabDeepDive Here's the juicy debrief: Retail investors: Like the health-conscious foodies, they went crazy, subscribing 2.12 times their quota! Clearly, Innova Captab's offerings tickled their taste buds.  #CaptabCrush or #HealthStockHype Non-institutional investors: These savvy sharks also took a healthy bite, subscribing 96% of their share. They smell potential, that's for sure! Bigwigs (QIBs): They were a bit more cautious, with only 44% subscription. Maybe they're waiting for a second helping? What's on the menu for Innova Captab? This IPO has two main courses: Fresh issue: A piping hot Rs 320 crore to fuel the company's growth, like a protein shake for a bodybuilder. Offer for Sale: Up to 55,80,357 existing shares from the promoters, basically like sharing grandma's secret soup recipe with the world. So, should you invest? Remember, the stock market is like a gym – gotta do your research before lifting those weights! Here are some things to consider: Innova Captab's track record: They've been in the pharma game for 25 years, churning out generic and branded drugs like a well-oiled pill press. The market: Pharma stocks are generally considered defensive, meaning they can be a safe haven during rough economic times. ️ Your risk appetite: Can you handle some market volatility, or are you a one-multivitamin-a-day kind of investor? Ultimately, the decision is yours. But hey, with an IPO that pops like a bottle of effervescent multivitamins, Innova Captab is definitely worth keeping an eye on! P.S. Don't forget to do your own due diligence before investing. This post is just a snack to whet your appetite, not a full-course financial meal! #InnovaCaptabIPO #PharmaBoom #InvestWisely

Final Decision on Today's Closing #SME IPOs: 1. Premier Roadlines: - The company offers general transportation services, project logistics, and oversized/overweight cargo transportation across India. - Company has Good Fundamentals but rising debt is a bit concerning - Company has decent Valuations - Demand is also decent, Latest #GMP is 37%. Premium recently fell from 45% to current levels Moderate Risk takers can apply in this IPO. LM is Hem Securities and Anchor's list is also strong. 2. Aztec Fluids & Machinery: - The company provides assortment of Printers, Printer consumables, and Printer Spares to a diverse range of industries. - Company has Strong Fundamentals - Valuations are also Good - Demand for this IPO is Strong, Latest #GMP is 45% which is Good. Even Safe Players can Apply in this SME IPO since LM is Hem Securities and GMP is stable. 3. Piotex Industries: - The Company is engaged in contract manufacturing and trading of yarns, fabrics, and cotton bales for various purposes such as apparel and home textiles. - Fundamentals are Strong but debt/equity is 0.5 - Valuations are decent - Demand for this SME IPO is increasing day by day; although Latest #GMP is just 32%. High Risk takers can apply in Piotex IPO because GMP is not so high and it involves risk. LM is Beeline whose previous track is really Good. #IPO #IPOAlert #SME #SMEIPO #StockMarketindia

Innova Captab IPO: Big Bets on CDMO Boom? 💰 Innova Captab's IPO opened today, and the buzz is palpable! As an investor, I'm intrigued by their potential as a leading player in India's booming Contract Development and Manufacturing Organization (CDMO) space especially since its a Pharma stock. But, it's not all sunshine and rainbows. Here's what's on my mind: The good: Strong market position: Innova Captab boasts a diverse clientele, including major pharma players. Their focus on complex generics and niche APIs gives them an edge. Experienced management: The leadership team has a proven track record in the industry, inspiring confidence. Growth potential: The Indian CDMO market is expected to reach $20 billion by 2025, offering ample room for Innova Captab to scale. The not-so-good: Valuation concerns: While the price band seems reasonable, the final price will be crucial in determining the IPO's attractiveness. Competition: The CDMO space is getting crowded, with established players and new entrants vying for market share.  Risks of execution: Expanding capacity and maintaining quality control are crucial challenges for any growing CDMO. What do you think? Is Innova Captab an attractive investment? Share your thoughts and insights in the comments below! #InnovaCaptabIPO #CDMO #IndianPharma #Investment P.S. Remember, this is not financial advice. Always do your own research before investing!

Nephro Care India Ltd. launched its SME IPO with a fresh issue of 45.84 lakh shares. The company is a comprehensive treatment center located in Kolkata, offering a wide range of clinical and lifestyle solutions, as well as renal insufficiency treatment for patients. The IPO is subscribed 715.78 times . Details for the IPO are:  🔸The company was listed on the exchange (NSE SME) on 28th June 2024. 🔸The market maker for Nephro's IPO is Ss Corporate Securities. 🔸Issue Type: Book Built Issue IPO. 🔸Listing date: 5th July 2024. For Educational Purposes Only #IPO #SMEIPO #NephroCare #HealthcareInnovation #InvestmentOpportunity #StockMarket #KolkataHealthcare #RenalTreatment #ClinicalSolutions #BookBuiltIssue #NSESME #MarketListing #InvestmentNews #FinancialGrowth #CorporateSecurities #MarketMaker #InvestmentStrategy #FinancialMarkets #BusinessGrowth #InvestorEducation #ArtharichInvestmentManager

The Indian stock market is set for a bustling week with four IPOs. GPT Healthcare aims to raise Rs 40 crore, Zenith Drugs sets its share price at Rs 79, Deem Roll Tech prices at Rs 129 to raise Rs 29 crore, and Juniper Hotels seeks ₹1,800 crore under the 'Hyatt' brand https://lnkd.in/geaEWy5P #ipos #initialpublicoffering #stockmarkets #investing #ipoinvesting #equity #newlisting #stocks #marketnews #investmentopportunity

🏥PharmEasy Rights Issue: CCI Greenlights Ranjan Pai, 360 One's Stake Acquisition. 📝 Summary: The Competition Commission of India (CCI) has approved the investment proposal by Manipal Group chairman Ranjan Pai's family office and 360 One in API Holdings, the parent company of PharmEasy. Ranjan Pai's stake acquisition positions him as one of the largest investors in PharmEasy, with an estimated stake exceeding 12%, alongside a board seat. This investment is part of PharmEasy's INR 3,500 Cr rights issue completed in October last year, involving prominent investors like Goldman Sachs, Prosus, and Temasek. 🔍 Key Points: - CCI's approval encompasses the subscription to class B CCPS of API Holdings by MEMG LLP and 360 ONE, aligning with Section 5(a)(i)(A) of the Competition Act, 2002. - Ranjan Pai's investment in PharmEasy signifies a strategic move, granting him significant influence within the online pharmacy giant. - PharmEasy's rights issue, aimed at reducing debt owed to Goldman Sachs, initially targeted INR 2,400 Cr but was raised to INR 3,500 Cr, reflecting investor confidence despite a valuation markdown. 💡 Insights: - PharmEasy's debt restructuring underscores the challenges faced by the startup, including valuation markdowns, funding constraints, and operational streamlining efforts. - Despite these challenges, PharmEasy has exhibited growth potential, recording a 16% YoY increase in operating revenue in FY23 while reducing losses by 16.23%. 🚀 Future Outlook: - With Ranjan Pai's substantial stake and board representation, PharmEasy aims to leverage strategic insights and financial support to navigate industry challenges and drive sustainable growth. - The CCI approval paves the way for further collaboration and expansion initiatives within the online pharmacy sector, positioning PharmEasy for enhanced market presence and value creation. 🎓 Conclusion: PharmEasy's successful rights issue and stake acquisition underscore its resilience and strategic vision amidst industry headwinds. With strong investor backing and regulatory approval, the company is well-positioned to capitalize on growth opportunities and reinforce its position as a leading player in the online pharmacy landscape. #PharmEasy #RightsIssue #CCIApproval #StakeAcquisition #Investment #OnlinePharmacy #RanjanPai #360One #APIHoldings #BusinessNews #MicroShots #NewsUpdates